Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 6:05 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1105–1128 of 8,147 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: GI Disorders Clear all
Completed Phase 2 Interventional Results available

Survivorship Promotion In Reducing IGF-1 Trial

NCT02431676
View directory record Official record
Conditions
Breast Cancer, Prostate Cancer, Lung Cancer, Colon Cancer, Melanoma of Skin, Endometrial Cancer, Liver Cancer, Pancreatic Cancer, Rectal Cancer, Kidney Cancer, Other Solid Malignant Tumors
Interventions
Metformin, Coach Directed Behavioral Weight Loss, Self-control weight loss
Drug · Behavioral
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 28, 2024 · Synced Oct 29, 2026, 6:05 AM EDT
Recruiting Phase 2 Interventional

Stool Transplants to Treat Refractory Clostridium Difficile Colitis

NCT02127398
View directory record Official record
Conditions
Clostridium Difficile Colitis
Interventions
fecal microbiota
Biological
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 29, 2026, 6:05 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Transdermal Administration by a Novel Wireless Iontophoresis Device

NCT06351852
View directory record Official record
Conditions
Spinal Cord Injuries, Constipation, Fecal Incontinence, Neurogenic Bowel
Interventions
Combination of Neostigmine and Glycopyrrolate, I-Box by Dynatronics
Drug · Device
Lead sponsor
James J. Peters Veterans Affairs Medical Center
Federal
Eligibility
18 Years to 89 Years
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Sep 17, 2025 · Synced Oct 29, 2026, 6:05 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma

NCT01154452
View directory record Official record
Conditions
Adult Alveolar Soft Part Sarcoma, Adult Angiosarcoma, Adult Desmoplastic Small Round Cell Tumor, Adult Epithelioid Hemangioendothelioma, Adult Epithelioid Sarcoma, Adult Extraskeletal Myxoid Chondrosarcoma, Adult Extraskeletal Osteosarcoma, Adult Fibrosarcoma, Adult Leiomyosarcoma, Adult Liposarcoma, Adult Malignant Mesenchymoma, Adult Malignant Peripheral Nerve Sheath Tumor, Adult Rhabdomyosarcoma, Adult Synovial Sarcoma, Adult Unclassified Pleomorphic Sarcoma, Chondrosarcoma, Clear Cell Sarcoma of the Kidney, Conjunctival Kaposi Sarcoma, Dermatofibrosarcoma Protuberans, Gastrointestinal Stromal Tumor, Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Metastatic Osteosarcoma, Ovarian Sarcoma, Recurrent Adult Soft Tissue Sarcoma, Recurrent Adult Unclassified Pleomorphic Sarcoma of Bone, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Kaposi Sarcoma, Recurrent Osteosarcoma, Recurrent Uterine Corpus Sarcoma, Small Intestine Leiomyosarcoma, Stage III Adult Soft Tissue Sarcoma, Stage III Uterine Sarcoma, Stage IV Adult Soft Tissue Sarcoma, Stage IV Uterine Sarcoma, Unclassified Pleomorphic Sarcoma of Bone
Interventions
Gamma-Secretase Inhibitor RO4929097, Laboratory Biomarker Analysis, Pharmacological Study, Vismodegib
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 15, 2018 · Synced Oct 29, 2026, 6:05 AM EDT
Completed Phase 2Phase 3 Interventional

Efficacy, Safety, and Tolerability Study of RP-G28 in Subjects With Lactose Intolerance

NCT02673749
View directory record Official record
Conditions
Lactose Intolerance
Interventions
RP-G28, Placebo
Drug · Other
Lead sponsor
Ritter Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
377 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 4, 2018 · Synced Oct 29, 2026, 6:05 AM EDT
Terminated Phase 2 Interventional Results available

AZD0530 (NSC 735464) in Treating Patients With Previously Treated Metastatic Colon Cancer or Rectal Cancer

NCT00397878
View directory record Official record
Conditions
Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum, Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IV Colon Cancer, Stage IV Rectal Cancer
Interventions
saracatinib, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 20, 2019 · Synced Oct 29, 2026, 6:05 AM EDT
Completed Phase 2 Interventional

A Study of Cetuximab in Patients Who Have Stage IV Colorectal Cancer

NCT00055419
View directory record Official record
Conditions
Colorectal Neoplasms
Interventions
Cetuximab
Biological
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
744 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
29
States / cities
Bakersfield, California • Los Angeles, California • Denver, Colorado + 26 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2010 · Synced Oct 29, 2026, 6:05 AM EDT
Recruiting Not applicable Interventional

The Use of Body Surface Gastric Mapping in Assessing the Clinical Success of G-POEM

NCT06493032
View directory record Official record
Conditions
Gastroparesis
Interventions
Gastric Alimetry System
Device
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 29, 2026, 6:05 AM EDT
Not yet recruiting Not applicable Interventional

Sling-Fiber Preservation POEM vs. Conventional POEM for Reducing Post-POEM GERD

NCT07178821
View directory record Official record
Conditions
Achalasia, Esophageal, GERD (Gastroesophageal Reflux Disease)
Interventions
Conventional POEM, Sling Fiber-Preserving POEM
Procedure
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Oct 22, 2025 · Synced Oct 29, 2026, 6:05 AM EDT
Completed Phase 1 Interventional

A Lactation Study in Women Who Are Breastfeeding or Pumping and Are Receiving Linaclotide Therapeutically

NCT02220348
View directory record Official record
Conditions
Breast Feeding, Constipation, Irritable Bowel Syndrome
Interventions
linaclotide
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
2
States / cities
Iowa City, Iowa • Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Dec 19, 2020 · Synced Oct 29, 2026, 6:05 AM EDT
Terminated Phase 2 Interventional Results available

Study of Ruxolitinib in Colorectal Cancer Patients

NCT02119676
View directory record Official record
Conditions
CRC (Colorectal Cancer)
Interventions
Ruxolitinib, Regorafenib, Placebo
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
396 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
57
States / cities
Chandler, Arizona • Gilbert, Arizona • Mesa, Arizona + 54 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2018 · Synced Oct 29, 2026, 6:05 AM EDT
Terminated Phase 2 Interventional Results available

Combination Chemotherapy and Bevacizumab in Treating Patients With Stage IV Colorectal Cancer

NCT00449163
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Bevacizumab, Floxuridine, Irinotecan, Leucovorin
Biological · Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 120 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 11, 2017 · Synced Oct 29, 2026, 6:05 AM EDT
Completed No phase listed Observational

Assessing Drivers and Barriers to Follow-Up Screening for Anal Cancer in Men Who Have Sex With Men

NCT00501306
View directory record Official record
Conditions
Anal Cancer
Interventions
Not listed
Lead sponsor
Laser Surgery Care
Other
Eligibility
18 Years to 85 Years · Male only
Enrollment
195 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 23, 2011 · Synced Oct 29, 2026, 6:05 AM EDT
Not yet recruiting Not applicable Interventional

The Mechanism Underlying the Analgesic Effect of the Music of IBS Pain

NCT06706778
View directory record Official record
Conditions
Abdominal Pain/ Discomfort, Irritable Bowel Syndrome
Interventions
Music intervention
Behavioral
Lead sponsor
Yale University
Other
Eligibility
18 Years to 50 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 27, 2026 · Synced Oct 29, 2026, 6:05 AM EDT
Terminated Not applicable Interventional

The Significance of Sentinel Node Analysis in Colon Cancer

NCT00419978
View directory record Official record
Conditions
Colon Cancer
Interventions
Colectomy
Procedure
Lead sponsor
Legacy Health System
Other
Eligibility
18 Years to 85 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 4, 2008 · Synced Oct 29, 2026, 6:05 AM EDT
Completed Not applicable Interventional Results available

A Culturally Sensitive Values-Guided Aid for End of Life Decision-Making

NCT00122135
View directory record Official record
Conditions
Congestive Heart Failure, Chronic Obstructive Pulmonary Disease, Cirrhosis, Colon Carcinoma, Lung Cancer, Chronic Kidney Disease
Interventions
Values Inventory (VI)
Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
55 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 14, 2015 · Synced Oct 29, 2026, 6:05 AM EDT
Completed Phase 1 Interventional

First-in-human Study of Oral TP-0903 (a Novel Inhibitor of AXL Kinase) in Patients With Advanced Solid Tumors

NCT02729298
View directory record Official record
Conditions
Advanced Solid Tumors, EGFR Positive Non-small Cell Lung Cancer, Colorectal Carcinoma, Recurrent Ovarian Carcinoma, BRAF-Mutated Melanoma
Interventions
TP-0903
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years and older
Enrollment
177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
16
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Denver, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2023 · Synced Oct 29, 2026, 6:05 AM EDT
Active, not recruiting Phase 3 Interventional

Evaluating Novel Therapies in ctDNA Positive GI Cancers

NCT05482516
View directory record Official record
Conditions
Colon Adenocarcinoma, Rectal Adenocarcinoma, Gastric Adenocarcinoma, Pancreatic Adenocarcinoma, Hepatocellular Carcinoma, Adenocarcinoma of Biliary Tract, Gallbladder Adenocarcinoma
Interventions
Atezolizumab, Bevacizumab
Drug
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 29, 2026, 6:05 AM EDT
Completed Not applicable Interventional

Telephone-Based Educational Intervention in Improving Communication Between Patients With Stage 0-III Cancer and Their Children

NCT02129049
View directory record Official record
Conditions
Breast Cancer, Cervical Cancer, Colon Cancer, Leukemia, Lymphoma, Malignant Neoplasm, Melanoma, Rectal Cancer
Interventions
educational intervention, telephone-based intervention, questionnaire administration
Other · Behavioral
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2014
U.S. locations
11
States / cities
Bozeman, Montana • Kennewick, Washington • Kirkland, Washington + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2016 · Synced Oct 29, 2026, 6:05 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Study of Effects of L-Arginine in Colitis and Colon Cancer

NCT01091558
View directory record Official record
Conditions
Ulcerative Colitis, Colon Cancer
Interventions
Not listed
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
204 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 31, 2017 · Synced Oct 29, 2026, 6:05 AM EDT
Completed Phase 1 Interventional

Phase I Study of Enadenotucirev and PD-1 Inhibitor in Subjects With Metastatic or Advanced Epithelial Tumors

NCT02636036
View directory record Official record
Conditions
Colorectal Cancer, Squamous Cell Carcinoma of the Head and Neck, Epithelial Tumor
Interventions
enadenotucirev, nivolumab
Biological
Lead sponsor
Akamis Bio
Industry
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
6
States / cities
Tucson, Arizona • Duarte, California • Santa Monica, California + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2021 · Synced Oct 29, 2026, 6:05 AM EDT
Completed Not applicable Interventional

Personalized Research on Diet in Ulcerative Colitis and Crohn's Disease

NCT03301311
View directory record Official record
Conditions
Inflammatory Bowel Diseases, Crohn Disease, Ulcerative Colitis, Indeterminate Colitis
Interventions
Specific Carbohydrate Diet (SCD), Modified Specific Carbohydrate Diet (MSCD)
Other
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
7 Years to 18 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
20
States / cities
Little Rock, Arkansas • Los Angeles, California • Oakland, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2022 · Synced Oct 29, 2026, 6:05 AM EDT
Terminated Phase 2 Interventional Results available

A Study of Zilovertamab Vedotin (MK-2140/VLS-101) in Participants With Solid Tumors (MK-2140-002)

NCT04504916
View directory record Official record
Conditions
Triple-negative Breast Cancer, Non-squamous Non-small-cell Lung Cancer, NSCLC, Estrogen-receptor-positive Breast Cancer, Progesterone-receptor-positive Breast Cancer, Estrogen-receptor-negative Breast Cancer, ER-negative Breast Cancer, Progesterone-receptor Negative Breast Cancer, PR-negative Breast Cancer, HER2-negative Breast Cancer, ER-positive Breast Cancer, PR-positive Breast Cancer, Platinum-resistant Ovarian Cancer, Gastric Cancer, Pancreatic Cancer
Interventions
Zilovertamab vedotin
Drug
Lead sponsor
VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
8
States / cities
Hollywood, Florida • Orlando, Florida • Boston, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 10, 2025 · Synced Oct 29, 2026, 6:05 AM EDT
Terminated No phase listed Observational

Longitudinal Study of Symptoms in Colorectal Cancer

NCT00777192
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Questionnaires
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
509 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2018
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 29, 2019 · Synced Oct 29, 2026, 6:05 AM EDT